DOCSLIB.ORG

Idweek16 Dalbavancin 1835.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Idweek16 Dalbavancin 1835.Pdf IDWEEK 2016 Activity of Dalbavancin Tested against Gram-positive Clinical Isolates Causing Skin For more information, please contact: 1835 Rodrigo E. Mendes, PhD and Skin Structure Infections in Pediatric Patients from USA Hospitals (2014 - 2015) JMI Laboratories [email protected] RE Mendes, HS Sader, MA Pfaller, M Castanheira, RK Flamm JMI Laboratories, North Liberty, IA, USA ABSTRACT INTRODUCTION RESULTS Table 2. Antimicrobial activity of dalbavancin and comparator agents against contemporary Gram-positive isolates causing SSSIs in children in the USA. CONCLUSIONS Background Dalbavancin was approved in the United States (USA; 2014) and Europe (2015) • Dalbavancin had MIC50/90 values of 0.03/0.06 μg/mL against S. aureus and CoNS, including the Organism/Groupa (no.) MIC (μg/mL): • Approved agents available for treatment of ABSSSI in children for the treatment of adults with acute bacterial skin and skin structure infections MRSA and MSSA subsets (Table 1). When tested against MRSA, dalbavancin MIC results were 8- to %Susceptible/%Intermediate/%Resistantc: Dalbavancin is approved for the treatment of acute bacterial skin Antimicrobial agentb MIC50 MIC90 Range are limited. Staphylococcal isolates comprised the majority of (ABSSSI) caused by susceptible isolates of Staphylococcus aureus, including 32-fold lower than those of daptomycin (MIC50/90, 0.25/0.5 μg/mL), vancomycin (MIC50/90, 0.5/1 μg/mL) and skin structure infections (ABSSSI) in adults. Current trials will MSSA (455) pathogens responsible for SSSI in children in the USA and a methicillin-susceptible (MSSA) and -resistant (MRSA) S. aureus, Streptococcus and linezolid (MIC50/90, 1/1 μg/mL; Table 2). Dalbavancin 0.03 0.06 0.008 — 0.12 100.0 - - further define dalbavancin therapeutic use, including for the Clindamycin ≤0.25 ≤0.25 ≤0.25 — >2 97.4 0.0 2.6 great proportion of these organisms were oxacillin-resistant pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus All tested agents showed in vitro activity against MSSA and MRSA (92.7 - 100.0% susceptible), Daptomycin 0.25 0.5 ≤0.12 — 1 100.0 - - treatment of ABSSSI in pediatric patients. This study provides an • (41.7%). anginosus group and vancomycin-susceptible Enterococcus faecalis. except for erythromycin (72.9% susceptible) against MSSA, and erythromycin (17.1% susceptible) Erythromycin 0.25 >8 ≤0.12 — >8 72.9 5.1 22.0 in vitro analysis of dalbavancin activity against isolates causing Levofloxacin ≤0.12 0.25 ≤0.12 — >4 94.7 0.0 5.3 Dalbavancin allows for very convenient administrations, which can be a single and levofloxacin (46.7% susceptible) against MRSA (Table 2). Linezolid 1 1 0.25 — 2 100.0 - 0.0 SSSI in children. • Dalbavancin demonstrated potent in vitro activity against these dose of 1500 mg or a dose of 1000 mg followed by 500 mg a week later. Tetracycline ≤0.5 ≤0.5 ≤0.5 — >8 94.7 0.2 5.1 • A total of 42.9% of CoNS isolates were oxacillin-resistant (Table 2). Dalbavancin MIC results were 8- TMP-SMX ≤0.5 ≤0.5 ≤0.5 — >4 99.6 - 0.4 Gram-positive isolates causing SSSI in children, and all Methods Moreover, current trials will further define dalbavancin therapeutic use, including Vancomycin 0.5 1 ≤0.12 — 1 100.0 0.0 0.0 to 16-fold lower than those of daptomycin (MIC50/90, 0.25/0.5 μg/mL), levofloxacin (MIC50/90, 0.25/1 MRSA (315) indicated species were susceptible to dalbavancin when for the treatment of ABSSSI in pediatric patients. Dalbavancin 0.03 0.06 0.008 — 0.06 100.0 - - 770 S. aureus, 167 β-hemolytic streptococci (BHS), 42 coagulase- μg/mL) and linezolid (MIC50/90, 0.5/1 μg/mL) against CoNS. Moreover, dalbavancin was 32-fold more applying the FDA breakpoints. Clindamycin ≤0.25 ≤0.25 ≤0.25 — >2 92.7 0.3 7.0 negative staphylococci (CoNS), 25 E. faecalis and 13 viridans active than vancomycin (MIC50/90, 1/2 μg/mL; Table 2). During pre-clinical development, dalbavancin has demonstrated potent in vitro Daptomycin 0.25 0.5 ≤0.12 — 1 100.0 - - group streptococci (VGS) causing SSSI were collected from Erythromycin >8 >8 ≤0.12 — >8 17.1 2.5 80.3 • These data warrant further development of dalbavancin for All E. faecalis isolates were inhibited by dalbavancin (MIC , 0.03/0.06 μg/mL) at ≤0.06 μg/mL, Levofloxacin 4 >4 ≤0.12 — >4 46.7 1.3 52.1 activity against S. aureus (including MRSA), streptococci and vancomycin– • 50/90 treatment of SSSI in children, provided safety and tolerability are children (<18 years old) in the USA (2014 - 2015). Bacteria were except for one vancomycin-resistant isolate (Table 1). Other tested agents (92.0 – 100.0% Linezolid 1 1 0.25 — 1 100.0 - 0.0 susceptible enterococci. In vitro activity has also been demonstrated against Tetracycline ≤0.5 1 ≤0.5 — >8 93.0 1.6 5.4 satisfactory. identified by standard algorithms and MALDI-TOF-MS. susceptible) were also active against E. faecalis, with the exception of tetracycline (24.0% TMP-SMX ≤0.5 ≤0.5 ≤0.5 — >4 97.8 - 2.2 heterogeneous vancomycin–intermediate (hVISA; MIC range, 0.12 – 0. 5 μg/mL) Susceptibility testing was performed by CLSI methods (M07-A10); susceptible; Table 2). Vancomycin 0.5 1 ≤0.12 — 1 100.0 0.0 0.0 and vancomycin–intermediate S. aureus (VISA; 0.5 – 2 μg/mL), and other Gram– CoNS (42)d interpretation of MICs used CLSI criteria. Dalbavancin 0.03 0.06 0.008 — >0.25 - - - positive isolates less often recovered from human clinical specimens. This report • Dalbavancin was up to 32-fold more active than ampicillin (MIC50/90, ≤0.5/1 μg/mL), daptomycin Oxacillin 0.5 >2 ≤0.25 — >2 57.1 - 42.9 REFERENCES Clindamycin ≤0.25 >2 ≤0.25 — >2 78.6 2.4 19.0 1. Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW (2014). Once-weekly Results describes dalbavancin in vitro activity and potency when tested against a (MIC50/90, 1/1 μg/mL), linezolid (MIC50/90, 1/2 μg/mL), levofloxacin (MIC50/90, 1/2 μg/mL) and vancomycin (MIC , 1/2 μg/mL) against the E. faecalis population (Table 2). Daptomycin 0.25 0.5 ≤0.12 — 1 100.0 - - dalbavancin versus daily conventional therapy for skin infection. N Engl J Med 370: 2169-2179. contemporary (2014 – 2015) collection of Gram–positive isolates responsible for 50/90 Erythromycin 0.25 >8 ≤0.12 — >8 50.0 0.0 50.0 2. Citron DM, Tyrrell KL, Goldstein EJ (2014). Comparative in vitro activities of dalbavancin and Dalbavancin had MIC50/90 values of 0.03/0.06 μg/mL against S. SSSI recovered from a pediatric patient population in USA medical centers. Levofloxacin 0.25 1 ≤0.12 — >4 90.5 0.0 9.5 seven comparator agents against 41 Staphylococcus species cultured from osteomyelitis aureus and CoNS, including methicillin-resistant (MRSA) and • Dalbavancin was very active against BHS (MIC50/90, 0.008/0.03 μg/mL) and VGS (MIC50/90, Linezolid 0.5 1 ≤0.12 — 1 100.0 - 0.0 infections and 18 VISA and hVISA strains. Diagn Microbiol Infect Dis 79: 438-440. Tetracycline ≤0.5 1 ≤0.5 — >8 92.9 0.0 7.1 0.008/0.015 μg/mL), inhibiting 100% of these isolates at ≤0.06 and ≤0.03 μg/mL, respectively (Tables 3. Clinical and Laboratory Standards Institute (2015). M07-A10. Methods for dilution antimicrobial -susceptible (MSSA) S. aureus subsets. When tested against TMP-SMX ≤0.5 ≤0.5 ≤0.5 — 4 95.2 - 4.8 susceptibility tests for bacteria that grow aerobically; Approved Standard - Tenth edition. Wayne, 1 and 2). Vancomycin 1 2 ≤0.12 — 2 100.0 0.0 0.0 MRSA, dalbavancin MICs were 8- to 32-fold lower than those of PA, USA. METHODS E. faecalis (25) daptomycin (MIC , 0.25/0.5 μg/mL), vancomycin (MIC , 0.5/1 • Dalbavancin (MIC , 0.008/0.03 μg/mL), ceftriaxone (MIC , ≤0.06/≤0.06 μg/mL) and penicillin Dalbavancin 0.03 0.06 ≤0.015 — >2 96.0e - - 4. Clinical and Laboratory Standards Institute (2016). M100-S26. Performance standards for 50/90 50/90 50/90 50/90 antimicrobial susceptibility testing: 26th Informational Supplement. Wayne, PA, USA. Bacterial isolates (MIC , ≤0.06/≤0.06 μg/mL) were the most active agents against BHS, although other tested agents Ampicillin ≤0.5 1 ≤0.5 — 1 100.0 - 0.0 μg/mL) and linezolid (MIC50/90, 1/1 μg/mL). These agents showed 50/90 Daptomycin 1 1 0.5 — 2 100.0 - - 5. DalvanceTM Package Insert (2016). Available at http://www.allergan.com/assets/pdf/dalvance_pi. 100.0% susceptibility against MRSA, and clindamycin also had a A total of 770 S. aureus, 167 β-hemolytic streptococci (BHS), 42 coagulase- also showed susceptibility rates >90.0%, except for tetracycline (84.4%; Table 2). Levofloxacin 1 2 ≤0.5 — >4 92.0 0.0 8.0 Accessed February 2016. Linezolid 1 2 0.5 — 2 100.0 0.0 0.0 6. Dunne MW, Puttagunta S, Giordano P, Krievins D, Zelasky M, Baldassarre J (2016). A high (92.7%) susceptibility rate. Dalbavancin (MIC , 0.03/0.06 negative staphylococci (CoNS), 25 E. faecalis and 13 viridans group streptococci Tetracycline >8 >8 ≤1 — >8 24.0 0.0 76.0 randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial 50/90 • All VGS isolates were susceptible to dalbavancin (MIC100, 0.03 μg/mL) with MIC results 32- to 64-fold (VGS) causing SSSI were collected from children (<18 years old) in the USA Vancomycin 1 2 ≤0.5 — >16 96.0 0.0 4.0 skin and skin structure infection.
Load more

Recommended publications
  • Dalvance Generic Name: Dalbavancin Manufacturer1: DURATA Therapeutics Drug Class1,2,3,4: Antibiotic
    Brand Name: Dalvance Generic Name: dalbavancin Manufacturer1: DURATA therapeutics Drug Class1,2,3,4: Antibiotic Uses: Labeled Uses1: Treatment of adult patients with acute bacterial skin and skin structure infections caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group (including S. anginosus, S. intermedius, S. constellatus) Mechanism of Action:1,2,3,4 This drug is a lipoglycopeptide which binds to the D-alanyl-D-alanine terminus of the stem pentapeptide in nascent cell wall. Through this above mechanism it prevents cross-linking and interferes with cell wall synthesis. Dalbavancin is bactericidal in vitro against Staphylococcus aureus and Streptococcus pyogenes. Pharmacokinetics1,2,3,4 Tmax End of infusion time Vd 7-13L t1/2 346 hours Clearance .0513 l/h Protein binding (albumin) 93% (primarily to albumin) Bioavailability 100% Metabolism1,2,3,4: A minor metabolite- hydroxy-dalbavancin has been observed in the urine of healthy subjects, however quantifiable plasma concentrations have not been observed. Elimination1,2,3,4: Urine (33% as unchanged drug, 12% as hydroxy metabolite) Feces (20%) Efficacy: Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection. N Engl J Med 2014; 370:2169-2179. Study Design: Double blind, double dummy, randomized controlled study Description of Study: Discover 1 and Discover 2 were international, multicenter, randomized trials conducted from 2011 through 2012 at 54 and 86 investigative sites, respectively. The studies had the same design. Patients with acute bacterial skin and skin-structure infection were stratified then randomly assigned to receive dalbavancin intravenously on days 1 and 8 or vancomycin intravenously for at least 3 days with the option to switch to oral linezolid to complete 10 to 14 days of therapy.
    [Show full text]
  • Criteria for Use of Dalbavancin for Acute Bacterial Skin/Soft Tissue Infection (Abssti)
    Criteria for Use of Dalbavancin for Acute Bacterial Skin/Soft Tissue Infection (abSSTI) 1. Patients meeting any of the following are NOT ELIGIBLE for dalbavancin therapy: a. History of hypersensitivity reaction to lipoglycopeptide antibiotics (vancomycin, televancin, dalbavancin, oritavancin). b. Patients with acute bacterial skin or skin structure infections such as superficial/simple cellulitis/erysipelas, impetiginous lesion, furuncle, or simple abscess that only requires surgical drainage for cure. c. Infection thought to be caused by gram-negative bacteria d. Infection due to an organism suspected or known to be resistant to dalbavancin or vancomycin 2. For outpatient use (i.e. ED) a. Contact infectious disease for authorization: ABX approval pager (see ON-CALL schedule) b. The following clinical criteria must be met: i. Pre-antibiotic blood cultures must be drawn. ii. Clinical condition expected to require ≥ 24 hours of IV antibiotics – must not qualify for oral antibiotic therapy. iii. Presence of cellulitis, major abscess or a wound infection associated with at least 75cm2 of erythema highly suspected or known to be caused by gram-positive bacteria. iv. The size of the infection must be clearly documented and/or outlined prior to leaving the ED, preferably with a photograph. v. Patient to be discharged to home ± home health (not to skilled nursing facility). c. Required follow up must be set up prior to leaving the ED: i. Must document patient contact info for follow up, preferably reliable cell phone number. ii. Must have follow up within 48-72H with Dr. Turnipseed (916-765-0196) or Rominski. 1. Email patient name, MRN, and phone number.
    [Show full text]
  • Dalbavancin (Dalvance®)
    DalbavancinDalbavancin (Dalvance (Dalvance®)®) IV Only Use requires formal ID Consult Activity: Coverage against Staphylococcus aureus (including MSSA and MRSA), Streptococcus pyogenes, Streptococcus agalactiae (Group B Strep.) and Streptococcus anginosus group (including S. anginosus, S. intermedius, S. constellatus) No clinical data, but activity in vitro vs. Enterococcus faecalis (vancomycin-susceptible strains only), Enterococcus faecium (vancomycin-susceptible strains only), vancomycin-intermediate S. aureus (not vancomycin-resistant strains) Criteria for Use: Treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive isolates Unable to use vancomycin (due to intolerance, MIC >2mg/L, or infection unresponsive to vancomycin despite therapeutic concentrations) Unable to use other agents (refer to empiric therapy for ABSSSI) Unacceptable Uses: Infections due to vancomycin-resistant enterococci Contraindicated in patients with known hypersensitivity to dalbavancin. Due to the possibility of cross-reactivity to glycopeptide, avoid in patients with previous glycopeptide hypersensitivity due to long half-life Dosing in Adults: Standard dose: Administration should be over 30 minutes 1 Dose Regimen: 1500mg IV once 2 Dose Regimen: 1000mg IV once, then 500mg IV on day 8 Renal dose adjustment: 1 Dose Regimen CrCl <30 mL/min 1125 mg IV 2 Dose Regimen CrCl <30 mL/min: 750mg IV once, then 325mg IV day 8 If receiving regularly scheduled hemodialysis: No dosage adjustment No hepatic dose adjustment anticipated Monitoring: Baseline BUN/Scr, AST/ALT/bili, CBC w/ diff, infusion-related reactions Considerations for Use: In clinical trials, 6 (0.9%) patients in the dalbavancin arm had ALT elevations greater than 5x ULN including 3 with ALT >10x ULN.
    [Show full text]
  • CLSI Subcommittee on Antimicrobial Susceptibility Testing CLSI AST News Update Janet a Hindler, MCLS MT(ASCP) F(AAM), Editor Audrey Schuetz, MD, MPH, FCAP, Editor
    Volume 3, Issue 1 Winter 2018 CLSI Subcommittee on Antimicrobial Susceptibility Testing CLSI AST News Update Janet A Hindler, MCLS MT(ASCP) F(AAM), Editor Audrey Schuetz, MD, MPH, FCAP, Editor The CLSI Outreach Working Group (ORWG) is providing this Newsletter to highlight some recent issues related to antimicrobial susceptibility Inside This Issue: testing (AST) and reporting. We are listing links to some new educational materials and reminding you where you can find information about the 21st Century Cures Act – Exciting News .......4 CLSI AST Subcommittee proceedings. Feature Article - Understanding Pharmacokinetics (PK) and Pharmacodynamics (PD) .................................5 CLSI 2018 AST Webinar: M100, M02, and M07 Updates Case Study - Direct Detection of MRSA/MSSA This hour and a half webinar will help you identify the latest changes in from Positive Blood Cultures .........................9 the updated editions of M100, M02, and M07. Don’t miss the opportunity to learn directly from leading AST experts. Burning Question - When Should Clinical Microbiology Laboratories Perform Date Options: Carbapenemase Detection Tests? ..............12 February 7, 2018 | 1:00-2:30 PM Eastern (US) Time Respiratory Illnesses and the Need for February 8, 2018 | 3:00-4:30 PM Eastern (US) Time Antibiotic Stewardship ..................................15 Moderator: Janet A. Hindler, MCLS MT(ASCP) F(AAM) Antimicrobial Susceptibility Testing of Speakers: Romney M. Humphries, PhD, D(ABMM) Bacteria Associated with Community- Audrey Schuetz, MD, MPH, FCAP Acquired Pneumonia .....................................18 Nonmember Price: $99.00. | Earn 1.5 PACE® CE credits. Hot Topic - Candida auris ..............................20 Member discounts apply. Register today. What does the CLSI AST Subcommittee do? The first edition of the CLSI AST News Update (Volume 1, Issue 1, Spring 2016) described details about the organization and operation of the CLSI AST Subcommittee.
    [Show full text]
  • APPLICATION for AVYCAZ® (Avibactam and Ceftazidime) for Injection, DALVANCE® (Dalbavancin) for Injection, and TEFLARO® (Ceftaroline Fosamil) Injection
    APPLICATION FOR AVYCAZ® (avibactam and ceftazidime) for injection, DALVANCE® (dalbavancin) for injection, and TEFLARO® (ceftaroline fosamil) for injection myAbbVie Assist provides free medicine to qualifying patients. We review all applications on a case-by-case basis. Participation in our program is free; we do not collect any fees from people seeking our assistance. CHECKLIST FOR SUBMITTING AN APPLICATION IF YOU ARE THE PRESCRIBER, COMPLETE PAGE 2 o SECTION 1: Prescriber Information o SECTION 2: Patient Information . If this a request for replacement product, please submit a claim denial dated within 60 days. o SECTION 3: Product information o SECTION 4: Prescriber Certification and Signature IF YOU ARE A PATIENT, COMPLETE PAGE 3. PLEASE READ PAGE 4 o SECTION 5: Patient Information o SECTION 6: Financial Information . Also include proof of income for all in household. A copy of your current federal tax return is preferred. o SECTION 7: Insurance Information . If you have Insurance, include front and back copies of all insurance cards. If you have insurance coverage, please attach list of your medical or prescription drug out of pocket costs. If you are taking multiple prescriptions, a printout from your pharmacy will be helpful. This information will help us review your eligibility for our program. o SECTION 8: Patient Consent and Signature . Carefully read the HIPAA authorization, patient terms of participation and privacy notice in Section 10 on Page 4. Provide your consent for eligibility determination by checking the box in Section 8. Confirm your understanding of our privacy policy by providing your signature and date in Section 8.
    [Show full text]
  • Outpatient Parenteral Antimicrobial Therapy for Infectious Diseases 3Ed
    Outpatient Parenteral Antimicrobial Therapy Handbook of For Infectious Diseases 3ed The Sponsored by Medicines Company ©2016 CRG Publishing, a Division of The Curry Rockefeller Group, LLC, and the Infectious Diseases Society of America All rights reserved. No part of the OPAT eHandbook may be reproduced in any form by any means (eg, electronically, mechanically, copied, recorded, or otherwise), or utilized by any information storage or retrieval system, without the written permission of CRG Publishing and the Infectious Diseases Society of America. For information, contact Rights and Permissions Coordinator, The Curry Rockefeller Group, Suite 410, 660 White Plains Road, Tarrytown, New York, 10591, USA. The Sponsored by Medicines Company Supported by Handbook of Outpatient Parenteral Antimicrobial Therapy For Infectious Diseases 3ed Akshay B. Shah, MD, MBA, FIDSA Anne H. Norris, MD Chair, OPAT Workgroup of IDSA Co-Chair, OPAT Guidelines Committee of IDSA Metro Infectious Disease Consultants Associate Professor of Medicine Editors Clinical Assistant Professor Perelman School of Medicine, University of Pennsylvania Wayne State University Philadelphia, PA Detroit, MI CRG PUBLISHING, A DIVISION OF THE CURRY ROCKEFELLER GROUP, LLC Geneve M. Allison, MD, MSc, FACP Ajay Mathur, MD, FACP Akshay B. Shah, MD, MBA, FIDSA Assistant Professor Regional VP Chair, OPAT Workgroup of IDSA Tufts University School of Medicine ID Care Metro Infectious Disease Consultants Clinical Assistant Professor Antonio C. Arrieta, MD David S. McKinsey, MD Wayne State University Division Chief, Infectious Diseases Physician Children’s Hospital of Orange County Infectious Disease Associates of Kansas City Nabin Shrestha, MD, MPH, FACP, FIDSA Infectious Disease Physician Kavita P. Bhavan, MD Sandra B.
    [Show full text]
  • Dalbavancin As Consolidation Therapy in Patients with Endocarditis And/Or Bloodstream Infection Produced By
    Hidalgo‑Tenorio et al. Ann Clin Microbiol Antimicrob (2019) 18:30 Annals of Clinical Microbiology https://doi.org/10.1186/s12941‑019‑0329‑6 and Antimicrobials RESEARCH Open Access DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram‑positive cocci Carmen Hidalgo‑Tenorio1* , David Vinuesa2, Antonio Plata3, Pilar Martin Dávila4, Simona Iftimie5, Sergio Sequera1, Belén Loeches6, Luis Eduardo Lopez‑Cortés7, Mari Carmen Fariñas8, Concepción Fernández‑Roldan1, Rosario Javier‑Martinez1, Patricia Muñoz9, Maria del Mar Arenas‑Miras10, Francisco Javier Martínez‑Marcos11, Jose Maria Miró12, Carmen Herrero13, Elena Bereciartua14, Samantha E. De Jesus1 and Juan Pasquau1 Abstract Objectives: To analyse the efectiveness of dalbavancin (DBV) in clinical practice as consolidation therapy in patients with bloodstream infection (BSI) and/or infective endocarditis (IE) produced by gram‑positive cocci (GPC), as well as its safety and pharmacoeconomic impact. Methods: A multicentre, observational and retrospective study was conducted of hospitalised patients with IE and/ or BSI produced by GPC who received at least one dose of DBV. Clinical response was assessed during hospitalization, at 3 months and at 1 year. Results: Eighty‑three patients with median age of 73 years were enrolled; 73.5% were male; 59.04% had BSI and 49.04% IE (44.04% prosthetic valve IE, 32.4% native IE, 23.5% pacemaker lead). The most frequently isolated microor‑ ganism was Staphylococcus aureus in BSI (49%) and coagulase‑negative staphylococci in IE (44.1%). All patients with IE were clinically cured in hospital; at 12 months, there was 2.9% loss to follow‑up, 8.8% mortality unrelated to IE, and 2.9% therapeutic failure rate.
    [Show full text]
  • Dalbavancin: a Nationwide Outpatient Experience in Physician Office Infusion Centers (Poics) Healix Infusion Therapy, Inc
    Lucinda J. Van Anglen, PharmD IDWeek 2015 Dalbavancin: A Nationwide Outpatient Experience in Physician Office Infusion Centers (POICs) Healix Infusion Therapy, Inc. #7 86 14140 SW Fwy, Ste. 400 Lucinda J. Van Anglen1, PharmD, Robin H. Dretler, MD2, Luu Quyen, MD3, Ramesh V. Nathan, MD, FIDSA4, Barry Statner, MD CM, FRCPC, FIDSA4, Fernando S. Alvarado, MD5 Sugar Land, TX 77478 281-295-4000 1 2 3 Healix Infusion Therapy, Inc., Sugar Land, TX; Infectious Disease Specialists of Atlanta, Atlanta, GA; Quyen Luu, MD, Macon, GA; [email protected] 4Mazur, Statner, Dutta, Nathan, PC, Thousand Oaks, CA; 5Infectious Disease Consultants, Altamonte Springs, FL Abstract, revised Results Discussion Background: Dalbavancin (DAL), a long-acting lipoglycopeptide, was recently approved for the Demographics Antibiotic Treatment Prior to DAL Adverse Events Requiring DAL Discontinuation This retrospective study described the outpatient use of DAL in POICs. treatment of acute bacterial skin and skin structure infections caused by susceptible gram- positive bacteria. With weekly administration, this agent may be beneficial for use in outpatient Characteristics (n=105) No. (%) 90 80 Pt Reason Onset Prior Antibiotics Outcome Almost half of pts (47%) initiated therapy in the POIC. DAL was used parenteral antimicrobial therapy (OPAT). We report clinical experience of OPAT use of DAL. Gender, male 57 (54%) Vancomycin Doxycycline Treated in POIC, Methods: A multi-center, retrospective database review was conducted of all patients (pts) 1* Dyspnea Immediate Oral doxycycline as a first-line therapy in 13 pts (12%) naïve to antibiotics. Age (years) 16 symptoms (sx) resolved receiving DAL in 16 POICs from July 2014 through March 2015.
    [Show full text]
  • DALVANCE (Dalbavancin) for Injection, for Intravenous Use ------WARNINGS and PRECAUTIONS------Initial U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION --------------------------DOSAGE FORMS AND STRENGTHS----------------- These highlights do not include all the information needed to use For injection: 500 mg of lyophilized powder in a vial for reconstitution (3) DALVANCE® safely and effectively. See full prescribing information for DALVANCE. --------------------------------CONTRAINDICATIONS----------------------------- Hypersensitivity to dalbavancin (4) DALVANCE (dalbavancin) for injection, for intravenous use -------------------------WARNINGS AND PRECAUTIONS---------------------- Initial U.S. Approval: 2014 • Serious hypersensitivity (anaphylactic) and skin reactions have been ---------------------------RECENT MAJOR CHANGES--------------------------- reported with glycopeptide antibacterial agents, including DALVANCE; • Dosage and Administration (2) 01/2016 exercise caution in patients with known hypersensitivity to glycopeptides. (5.1) --------------------------INDICATIONS AND USAGE----------------------------- • Rapid intravenous infusion of glycopeptide antibacterial agents can cause DALVANCE is indicated for acute bacterial skin and skin structure infections reactions. (5.2) (ABSSSI) caused by designated susceptible strains of Gram-positive • ALT elevations with DALVANCE treatment were reported in clinical microorganisms. (1.1) trials. (5.3) • Clostridium difficile-associated diarrhea (CDAD) has been reported with To reduce the development of drug-resistant bacteria and maintain the nearly all systemic antibacterial agents, including DALVANCE.
    [Show full text]
  • Antibacterial Prodrugs to Overcome Bacterial Resistance
    molecules Review Antibacterial Prodrugs to Overcome Bacterial Resistance Buthaina Jubeh , Zeinab Breijyeh and Rafik Karaman * Pharmaceutical Sciences Department, Faculty of Pharmacy, Al-Quds University, Jerusalem P.O. Box 20002, Palestine; [email protected] (B.J.); [email protected] (Z.B.) * Correspondence: [email protected] or rkaraman@staff.alquds.edu Academic Editor: Helen Osborn Received: 10 March 2020; Accepted: 26 March 2020; Published: 28 March 2020 Abstract: Bacterial resistance to present antibiotics is emerging at a high pace that makes the development of new treatments a must. At the same time, the development of novel antibiotics for resistant bacteria is a slow-paced process. Amid the massive need for new drug treatments to combat resistance, time and effort preserving approaches, like the prodrug approach, are most needed. Prodrugs are pharmacologically inactive entities of active drugs that undergo biotransformation before eliciting their pharmacological effects. A prodrug strategy can be used to revive drugs discarded due to a lack of appropriate pharmacokinetic and drug-like properties, or high host toxicity. A special advantage of the use of the prodrug approach in the era of bacterial resistance is targeting resistant bacteria by developing prodrugs that require bacterium-specific enzymes to release the active drug. In this article, we review the up-to-date implementation of prodrugs to develop medications that are active against drug-resistant bacteria. Keywords: prodrugs; biotransformation; targeting; β-lactam antibiotics; β-lactamases; pathogens; resistance 1. Introduction Nowadays, the issue of pathogens resistant to drugs and the urgent need for new compounds that are capable of eradicating these pathogens are well known and understood.
    [Show full text]
  • Idweek16 Dalbavancin 1834.Pdf
    IDWEEK 2016 Dalbavancin In Vitro Activity Obtained against Gram-positive Clinical Isolates Causing For more information, please contact: 1834 Rodrigo E. Mendes, PhD Bone and Joint Infections in USA and European Hospitals (2011 - 2015) JMI Laboratories [email protected] RE Mendes, RK Flamm, MA Pfaller, M Castanheira, HS Sader JMI Laboratories, North Liberty, IA, USA AMENDED ABSTRACT INTRODUCTION RESULTS Table 2. Antimicrobial activity of dalbavancin and comparator agents against Figure 1. Susceptibility profile of S. aureus clinical isolates causing BJIs in contemporary Gram-positive isolates causing BJIs in the USA and Europe. the adult (≥18 years old) and pediatric (≤17 years old) populations. Background Bone and joint infections (BJI) comprises a series of disorders, including septic arthritis, • S. aureus (65.3%) was the most common pathogen associated with BJI, followed by Organism/Groupa (no.) MIC (μg/mL): CoNS (11.9%) and BHS (11.6%; see Table 1). A total of 34.2% of S. aureus isolates %Susceptible/%Intermediate/%Resistantc: osteomyelitis, and infections in prosthetics joints. Osteomyelitis is an infection of the bone Antimicrobial agentb Osteomyelitis represents hard-to-treat infections that regularly MIC50 MIC90 Range were methicillin-resistant, while 61.0% of CoNS exhibited this phenotype (Tables 1 100 associated with either hematogenous dissemination or direct inoculation as a MSSA (428) involves the use of prolonged and systemic antibiotics. 90 and 2). Dalbavancin 0.06 0.06 ≤0.03 — 0.12 100.0 - - consequence of trauma or infection from contiguous tissues. Staphylococcus aureus 80 Clindamycin ≤0.25 ≤0.25 ≤0.25 — >2 97.9 0.0 2.1 Dalbavancin has demonstrated activity against Gram-positive 70 remains the most common pathogen responsible for acute infections, while Gram-negative Daptomycin 0.25 0.5 ≤0.12 — 1 100.0 - - Most tested agents demonstrated in vitro activity against MSSA (≥93.0% susceptible) .
    [Show full text]
  • Newest Lipoglycopeptides for the Management of Acute Bacterial Skin and Skin Structure Infections
    1.5 CONTACT HOURS 1.5 CONTACT HOURS David Mack / Science Source Newest lipoglycopeptides for the management of acute bacterial skin and skin structure infections By Allison M. Bell, PharmD; S. Travis King, PharmD; Katie E. Barber, PharmD; Kim G. Adcock, PharmD; Jamie L. Wagner, PharmD; and Kayla R. Stover, PharmD Abstract: Acute bacterial skin and skin kin and soft-tissue infections (SSTIs) repre- sent a broad spectrum of infections ranging structure infections (ABSSSIs) are some of S from superfi cial pyodermas to deep, necrotiz- the most commonly encountered infections ing infections.1,2 Most uncomplicated infections may worldwide. Hospitalizations as a result of be managed with topical therapies or simple surgical interventions; however, complicated SSTIs generally ABSSSIs are associated with high mortality. This require systemic antibiotic therapy and are likely to article discusses the role of oritavancin and require surgery.1,2 The common terminology through- dalbavancin, the two newest lipoglycopeptides, out the infectious disease literature has been SSTIs; however, in 2013, the FDA updated their industry in the context of the other available guidance for treatment of acute bacterial skin and I.V. infusion standard therapy options. skin structure infections and changed the terminology from complicated SSTIs to acute bacterial skin and Keywords: ABSSSIs, acute bacterial skin and skin structure infections, dalbavancin, daptomycin, lipoglycopeptides, oritavancin, telavancin, vancomycin www.tnpj.com The Nurse Practitioner • October 2018 31 Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved. Newest lipoglycopeptides for the management of acute bacterial skin and skin structure infections skin structure infections (absssis) to better describe pathogens still account for a signifi cant proportion the type of infection suitable for treatment with newer of nonpurulent cellulitis, particularly in ambulatory antibiotics.3 patients.1,9,10 absssis are some of the most commonly encoun- Within the past decade, methicillin-resistant S.
    [Show full text]